Exicure Inc XCUR

US Biotechnology
$1.22 β–Ό -0.81% ($-0.01)
⬇️ Below Yest. Low 🎈 Low Float 🎢 High Beta
Open $1.22
Prev Close $1.23
Day Range $1.21 – $1.23
52W Range $1.05 – $9.48
Market Cap $10.01M
Beta 3.95
EPS (TTM) $-1.30

πŸ“‹ Company Profile

IndustryBiotechnology
CountryUS
ExchangeNASDAQ NMS - GLOBAL MARKET
CurrencyUSD
IPO Date2018-05-09
Shares Out.6,370,000
Websiteexicuretx.com/ β†—
Phone13026365400
Employees8
Revenue$0
Gross Profit$0
Net Income-$1.1M
Free Cash Flow-$7.0M
Total Assets$11.4M
Total Liabilities$10.4M
Equity$977,000
About Exicure Inc

Exicure Inc is a clinical-stage biotechnology company focused on developing treatments for blood-related diseases, with an emphasis on small-molecule therapies that have the potential to benefit a broad range of patients. The company acquired GPCR Therapeutics USA and secured a license for GPC-100 (Burixafor), a clinical-stage small-molecule compound that inhibits the chemokine receptor CXCR4. GPC-100 has demonstrated the ability to effectively mobilize various cell types, including hematopoietic stem cells and lymphocytes, highlighting its broad therapeutic potential across multiple indications.

Exicure Inc is a publicly traded company under the ticker symbol XCUR on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.

πŸ“Š Analyst Ratings

6 analysts (2023-01-01)

Hold 3
Sell 1
Strong Sell 2

πŸ“° Latest News for XCUR

πŸ‘₯ Related Stocks